A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen

ValiSeek Limited0 sites8 target enrollmentOctober 2016

ConditionsCarcinoma, Non-Small-Cell Lung Adenocarcinoma

InterventionsVAL401

DrugsVAL401

Overview

Phase: Phase 2
Intervention: VAL401
Conditions: Carcinoma, Non-Small-Cell Lung
Sponsor: ValiSeek Limited
Enrollment: 8
Primary Endpoint: Progression-free Survival (PFS)
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.

Detailed Description

This is a Phase II, open label study to assess the efficacy, safety and tolerability of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma after failure of at least one prior chemotherapeutic regimen. Eligible patients will be enrolled as a single cohort and treated with VAL401, given as oral capsules. VAL401 is a formulation of Risperidone (active pharmaceutical ingredient) in a liquid lipid filled capsule.

Registry

clinicaltrials.gov

Start Date

October 2016

End Date

September 2017

Last Updated

7 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

ValiSeek Limited

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Pathologically confirmed diagnosis of Stage IIIB or Stage IV adenocarcinoma of the lung. Patients with mixed histology will be eligible if adenocarcinoma is the predominant histology.
•Measurable disease according to RECIST version 1.
•Prior chemotherapy for relapsed or metastatic non small cell lung cancer.
•Life expectancy of at least 3 months.
•Negative human chorionic gonadotropin (hCG) test in women of childbearing potential (defined as women ≤ 50 years of age or history of amenorrhea for ≤ 12 months prior to study screening). Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control e.g. barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices, during the entire duration of the study and for 1 month after the final administration of VAL
•Note that female patients may be surgically sterile (with appropriate documentation in the patient's medical records).
•Ability to give written, informed consent prior to any study-specific screening procedures with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
•Patient is capable of understanding the protocol requirements, is willing and able to comply with the study protocol procedures, and has signed the informed consent document.

Exclusion Criteria

•Radiotherapy or surgery (other than biopsy) within 4 weeks prior to Cycle 1 Day
•Any chemotherapy regimens (including investigational agents) with delayed toxicity with 6 weeks of Cycle 1 Day 1, or received any chemotherapy regimens given continuously or on a weekly basis which have limited potential for delayed toxicity within 2 weeks prior to Cycle 1 Day
•Palliative treatment regimens, and other concomitant drugs regimens are permitted with stable toxicity, and recording of all concomitant medications (including herbal).
•Pregnant or lactating female patients.
•Active hepatitis B or C or other active liver disease (other than malignancy).
•Any active, clinically significant, viral, bacterial, or systemic fungal infection within 2 weeks prior to Cycle 1 Day 1; other than cytomegalovirus which may be present providing any required concomitant anti-viral treatment is recorded appropriately.
•Known human immunodeficiency virus positivity.
•History of clinically significant cardiac condition, including ischemic cardiac event, myocardial infarction or unstable cardiac disease with 3 months prior to Cycle 1 Day
•Active brain metastases (defined as stable for \<4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids and/or leptomeningeal disease).
•Any known contraindications to Risperidone or patients who would not be eligible to receive the treatment as defined in the Special Warnings and Precautions section of the local label for Risperidone.

Arms & Interventions

VAL401 treatment

Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).

Intervention: VAL401

Outcomes

Primary Outcomes

Progression-free Survival (PFS)

Time Frame: 6 months

PFS is defined as the time from screening to disease progression (or death if the patient died before progression), with progression date nominally defined as the date the patient was withdrawn from the trial, where the Principal Investigator has determined by their professional discretion the patient has symptomatic disease progression.

Secondary Outcomes

Patient Quality of Life During VAL401 Treatment(6 months)
Number of Participants Reporting Adverse Events and Serious Adverse Events(6 months)
Peak Plasma Concentration (Cmax)(1 Day and 2 weeks)
Trough Plasma Concentration (Cmin)(1 Day and 2 weeks)
Overall Survival(6 months)
Number of Patients With Disease Control(6 months)
Plasma VAL401 Half-life (t 1/2)(1 Day and 2 weeks)